TrialAnnals of the rheumatic diseases2016

Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial.

Jeremy Sokolove et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.